Jackson Center, PA – May 28, 2026 – Halberd Corporation (OTC: HALB) announced today that NeuroSense AI, the behavioral intelligence platform in development by the Company, has achieved a new engineering milestone: end-to-end processing of externally supplied, long-form voice recordings—including direct-from-file ingestion, feature extraction, and automated visualization suitable for partner review and internal validation workflows.
As research programs scale—particularly those pairing voice with physiology, cardiopulmonary, and neurophysiology measures—the ability to analyze audio as delivered in the field (without re-recording through a microphone) is a prerequisite for reproducible analytics and for the validation and verification (V&V) documentation increasingly expected by sponsors and funding stakeholders. NeuroSense’s updated pipeline is designed to meet that bar by treating data provenance—format, sample rate, channel layout, and processing steps—as first-class inputs to analysis and reporting.
The milestone supports Halberd’s broader strategy of deploying multimodal behavioral intelligence across preclinical and translational research contexts. NeuroSense AI continues to integrate AI-assisted pattern recognition, including advanced interpretation workflows, with objective, time-resolved behavioral signals. Today’s progress extends that approach to human conversational audio used in structured assessment and longitudinal study settings, complementing the platform’s existing emphasis on objective behavioral sensing and interpretation in complex research environments.
Halberd and its collaborators remain focused on transparent methods: distinguishing research and analytics capabilities from any future diagnostic or therapeutic claims, and aligning software documentation with sponsor expectations as programs mature. The Company expects to provide additional technical updates as NeuroSense AI is exercised on larger, multimodal corpora and as integration pathways with complementary modalities—including EEG and biomarker streams—continue to harden.
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Established in 1974, the Mississippi State University College of Veterinary Medicine (MSU CVM) comprises six locations, catering to all 82 counties in Mississippi and the broader Southeastern United States. The primary campus, situated in Starkville, encompasses the Wise Center, home to the main teaching hospital known as the Animal Health Center. The faculty and staff of the MSU CVM Department of Comparative Biomedical Sciences cover fundamental scientific disciplines essential for veterinary education. MSU CVM is dedicated to an ethical approach in the treatment of animals, demonstrating a sincere passion and commitment.
About NeuroSense AI
NeuroSense AI is a behavioral intelligence platform in development by Halberd Corporation, designed to transform preclinical TBI research through multi-modal behavioral analysis and advanced AI interpretation. The platform combines ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring with Claude AI-powered pattern recognition to provide objective, continuous assessment of neurological function and recovery. For more information, visit NeuroSenseAI.ai
About Halberd Corporation.|
Halberd Corporation (OTC: HALB) is a technology holding company focused on developing breakthrough solutions for healthcare and medical applications. The Company’s portfolio includes innovative approaches to disease treatment, diagnostic technologies, and AI-powered healthcare platforms. Halberd is committed to improving human health outcomes through advanced technology development and strategic partnerships with leading research institutions.
Safe Harbor Notice
This press release contains forward-looking statements regarding Halberd Corporation’s business prospects and its NeuroSense AI platform. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2025, Halberd Corporation